Peer Reviewed
1
Document Type
Article
Publication Date
1-1-2013
Keywords
Animals, Chitosan, Cyclodextrins, Excipients, Gene Transfer Techniques, Humans, Liposomes, Lung, Polymers, RNA Interference, RNA, Small Interfering
Abstract
The emergence of RNAi offers a potentially exciting new therapeutic paradigm for respiratory diseases. However, effective delivery remains a key requirement for their translation into the clinic and has been a major factor in the limited clinical success seen to date. Inhalation offers tissue-specific targeting of the RNAi to treat respiratory diseases and a diminished risk of off-target effects. In order to deliver RNAi directly to the respiratory tract via inhalation, 'smart' non-viral carriers are required to protect the RNAi during delivery/aerosolization and enhance cell-specific uptake to target cells. Here, we review the state-of-the-art in therapeutic aerosol bioengineering, and specifically non-viral siRNA delivery platforms, for delivery via inhalation. This includes developments in inhaler device engineering and particle engineering, including manufacturing methods and excipients used in therapeutic aerosol bioengineering that underpin the development of smart, cell type-specific delivery systems to target siRNA to respiratory epithelial cells and/or alveolar macrophages.
Disciplines
Pharmacy and Pharmaceutical Sciences
Citation
Ramsey JM, Hibbitts AS, Barlow J, Kelly C, Sivadas N, Cryan SA. 'Smart' non-viral delivery systems for targeted delivery of RNAi to the lungs. Therapeutic Delivery. 2013;4(1):59-76.
PubMed ID
23323781
Link to this item at
http://epubs.rcsi.ie/spharmart/13/
DOI Link
10.4155/tde.12.133
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
Comments
This article is also available at http://www.future-science.com/doi/abs/10.4155/tde.12.133?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed